专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2008037449A3 USE OF AT LEAST ONE ISOFORM OF PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1 (PGRMC1) 审中-公开
标题翻译：使用孕激素受体膜成分1（PGRMC1）的至少一种同等物
公开(公告)号：WO2008037449A3
公开(公告)日：2008-06-12
申请号：PCT/EP2007008370
申请日：2007-09-26
申请人： PROTEOSYS AG , CAHILL MICHAEL , NEUBAUER HANS
发明人： CAHILL MICHAEL , NEUBAUER HANS
IPC分类号： G01N33/574 , A61K38/00
CPC分类号： A61K38/1796 , A61K38/00 , C07K14/721 , G01N33/57415 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/6896 , G01N33/74 , G01N2333/723 , G01N2800/102 , G01N2800/12 , G01N2800/24 , G01N2800/28 , G01N2800/2814 , G01N2800/32 , G01N2800/323 , G01N2800/367
摘要： The invention relates to the use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1 ) as diagnostic marker and/or therapeutic target for diseases associated with neogenin and/or DCC and/or for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one reagent that influences the function of at least one isoform of PGRMC1 for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one isoform of PGRMC1 for influencing abundance or subcellular localisation of at least one class of molecules interacting with PGRMC1, an assay kit for diagnosis and/or therapy of diseases associated with neogenin and/or DCC, comprising at least one isoform of PGRMC1 and/or at least one reagent that influences the function of at least one isoform of PGRMC1, the use of at least one isoform of PGRMC1 as diagnostic marker in diagnosis for diseases associated with aberrant biological phenotypes, wherein the phosphorylation status of the at least one isoform of PGRMC1 is determined/and or estimated and the use of at least one reagent for influencing the abundance and/or activity of isoforms of proteins for diagnosis and/or therapy of diseases associated with aberrant biological phenotypes, wherein said proteins are involved in protein interaction or multiprotein complexes with either at least one isoform of phosphorylated or non-phosphorylated PGRMC1.
摘要翻译：本发明涉及孕酮受体膜成分1（PGRMC1）的至少一种同种型作为与neogenin和/或DCC相关疾病的诊断标记和/或治疗靶标和/或制造用于治疗疾病的药物的用途与neogenin和/或DCC相关，使用至少一种影响PGRMC1的至少一种同种型的功能的试剂在制备用于治疗与neogenin和/或DCC相关的疾病的药物中的用途，使用至少一种 PGRMC1同种型用于影响与PGRMC1相互作用的至少一类分子的丰度或亚细胞定位，用于诊断和/或治疗与neogenin和/或DCC相关的疾病的测定试剂盒，其包含至少一种PGRMC1同种型和/或至少一种影响PGRMC1的至少一种同种型的功能的试剂，至少一种PGRMC1的同种型作为诊断与异常相关的疾病的诊断标志物其中确定/和估计PGRMC1的至少一种同种型的磷酸化状态，以及使用至少一种试剂影响蛋白质同工型的丰度和/或活性以诊断和/或治疗疾病与异常生物学表型相关，其中所述蛋白质与至少一种磷酸化或非磷酸化PGRMC1的同种型参与蛋白质相互作用或多蛋白复合物。

52. 发明申请

WO2007141043A2 MONOCLONAL ANTI-ANNEXIN A3 ANTIBODIES FOR THE DETECTION OF PROSTATE CARCINOMA 审中-公开
标题翻译： MONOCLONAL ANTI-ANNEXIN A3检测前列腺癌的抗体
公开(公告)号：WO2007141043A2
公开(公告)日：2007-12-13
申请号：PCT/EP2007/005134
申请日：2007-06-11
申请人： PROTEOSYS AG , SCHRATTENHOLZ, André
发明人： SCHRATTENHOLZ, André
IPC分类号： G01N33/574 , C07K16/18 , A61K39/395 , A61K38/00
CPC分类号： C07K16/3069 , G01N33/57434 , G01N2333/4718
摘要： The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies.
摘要翻译：本发明涉及用于诊断前列腺癌的方法，其包括用高度特异性抗体特别是单克隆抗体测定膜联蛋白A3，特别是细胞外膜联蛋白A3。本发明还涉及包含这种抗体的测试试剂。

53. 发明申请

WO2007039189A1 PHOSPHORYLATED OR NON-PHOSPHORYLATED MPR AS DIAGNOSTIC MARKER OR THERAPEUTIC TARGET 审中-公开
标题翻译：磷酸化或非磷酸化MPR作为诊断标记或治疗目标
公开(公告)号：WO2007039189A1
公开(公告)日：2007-04-12
申请号：PCT/EP2006/009351
申请日：2006-09-26
申请人： PROTEOSYS AG , CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
发明人： CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
IPC分类号： G01N33/574 , C07K14/72
CPC分类号： G01N33/743 , C07K14/721 , G01N33/564 , G01N33/57407 , G01N33/57415 , G01N33/57434 , G01N33/57484 , G01N33/6893 , G01N2333/723 , G01N2500/00 , G01N2800/12 , G01N2800/28 , G01N2800/367
摘要： The invention relates to the use of phosphorylated and/or non- phosphorylated membrane associated progesterone receptor component 1 (mPR or PGRMC 1 ) or progesterone membrane component 2 (PGRMC2), in particular of at least one isoform thereof, and to other proteins, in particular isoforms thereof, as diagnostic markers and/or therapeutic targets for diseases associated with aberrant biological phenotypes, reagents for influencing mPR and/or the abundance and/or activity of said other proteins and to the use of an appropriate assay.
摘要翻译：本发明涉及磷酸化和/或非磷酸化的膜相关孕激素受体组分1（mPR或PGRMC1）或孕酮酮组分2（PGRMC2），特别是其至少一种同种型和其它蛋白质在作为与异常生物表型相关的疾病的诊断标志物和/或治疗靶标，影响mPR的试剂和/或所述其它蛋白质的丰度和/或活性以及使用适当的测定法的特异性同种型。

54. 发明申请

WO2006058781A3 FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR PREVENTING/TREATING NEUROLOGICALLY-ASSOCIATED DISORDERS 审中-公开
标题翻译：杀虫剂，杀虫剂及相关化合物，用于预防/治疗神经病学相关疾病
公开(公告)号：WO2006058781A3
公开(公告)日：2007-03-22
申请号：PCT/EP2005012925
申请日：2005-12-02
申请人： PROTEOSYS AG , SOSKIC VUKIC , SCHRATTENHOLZ ANDRE
发明人： SOSKIC VUKIC , SCHRATTENHOLZ ANDRE
IPC分类号： A61K31/58 , A61K31/568 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28
CPC分类号： C07J73/005 , A61K31/568 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride and Dutasteride and its pharmaceutically acceptable derivatives, and combinations comprising said compounds . The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker- type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine -nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neurona SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy. The demonstrated inhibition of the MPTP appears to constitute a novel principle applicable to all pathological conditions which have underlying excitotoxic/mitochondrial mechanisms, like: amyotrophic lateral sclerosis, Alzheimer's disease, depression, epilepsy, multiple sclerosis, pain, Parkinson's disease, schizophrenia, traumatic brain and spinal chord injury, stroke and other ischemic conditions in the brain.
摘要翻译：本发明涉及4-氮杂甾烷化合物，特别是非那雄胺和度他雄胺及其药学上可接受的衍生物的新药物用途，以及包含所述化合物的组合。本发明还通常特征在于通过振动筛型电压门控钾通道的β亚单位和/或通过溶质载体家族25，特别是Aralar（成员12）和腺嘌呤核苷酸转运体1的成员的神经保护条件的调节剂化合物的使用＆2（成员4和5）和/或通过4-硝基苯基磷酸酶结构域和非神经元SNAP25样蛋白质同系物1（NIPSNAP 1）作为神经保护药物，特别是作为预防和/或治疗神经疾病的药物如痴呆症，帕金森病，阿尔茨海默病，精神分裂症或癫痫症。所显示的MPTP的抑制似乎构成适用于具有潜在兴奋性毒素/线粒体机制的所有病理状况的新颖原理，例如：肌萎缩性侧索硬化，阿尔茨海默病，抑郁症，癫痫，多发性硬化，疼痛，帕金森病，精神分裂症，创伤性脑和脊髓损伤，脑卒中等缺血状况。

55. 发明申请

WO2006125580A1 ANNEXIN FOR CANCER RISK ASSESSMENT 审中-公开
标题翻译：癌症风险评估附录
公开(公告)号：WO2006125580A1
公开(公告)日：2006-11-30
申请号：PCT/EP2006/004818
申请日：2006-05-22
申请人： ProteoSys AG , CAHILL, Michael , SCHRATTENHOLZ, André
发明人： CAHILL, Michael , SCHRATTENHOLZ, André
IPC分类号： G01N33/574
CPC分类号： G01N33/57434 , G01N33/57446 , G01N2333/4718
摘要： The invention relates to the use of at least one annexin protein for the treatment of cancer, in particular of the urogenital and/or intestinal tract, and to a method for diagnosing cancer, particularly of the urogenital and/or intestinal tract, and/or for discrimination between cancerous and non-cancerous tissue.
摘要翻译：本发明涉及至少一种膜联蛋白用于治疗癌症，特别是泌尿生殖道和/或肠道的用途，以及用于诊断特别是泌尿生殖和/或肠道的癌症的方法和/或用于鉴别癌和非癌组织。

56. 发明申请

WO2006108666A1 MEFLOQUINE, NELFINAVIR AND SAQUINAVIR AS NOVEL AGENTS FOR NEURODEGENERATIVE AND (NEURO-) INFLAMMATORY DISEASES 审中-公开
标题翻译： MEFLOQUINE，NELFINAVIR和SAQUINAVIR作为神经损伤和（NEURO-）炎症疾病的新药物
公开(公告)号：WO2006108666A1
公开(公告)日：2006-10-19
申请号：PCT/EP2006/003437
申请日：2006-04-13
申请人： PROTEOSYS AG , SCHRATTENHOLZ, André
发明人： SCHRATTENHOLZ, André
IPC分类号： A61K31/4709 , A61K31/4725 , A61P17/06 , A61P25/06 , A61P25/28
CPC分类号： A61K31/4709 , A61K31/4725
摘要： The present invention generally relates to the neuroprotective, anti-apoptotic and anti-inflammatory activity of mefloquine, nelfinavir and saquinavir and derivatives thereof based on recently discovered interactions with prohibitin and estrogen receptors and the inhibition of mitochondrial voltage- dependent anion channel 1. Thus, mefloquine, nelfinavir and saquinavir and derivatives thereof may be used as medicaments for the prevention and/or treatment of neurodegenerative and inflammatory, particularly neuroinflammatory diseases.
摘要翻译：本发明一般涉及甲氟喹，奈非那韦和沙奎那韦及其衍生物的神经保护，抗凋亡和抗炎活性，其基于最近发现的与禁食和雌激素受体的相互作用以及线粒体电压依赖性阴离子通道1的抑制。因此，甲氟喹，奈非那韦和沙奎那韦及其衍生物可用作预防和/或治疗神经变性和炎症，特别是神经炎症性疾病的药物。

57. 发明申请

WO2006029836A2 BREAST CANCER PROTEINS 审中-公开
标题翻译：乳腺癌蛋白
公开(公告)号：WO2006029836A2
公开(公告)日：2006-03-23
申请号：PCT/EP2005/009871
申请日：2005-09-14
申请人： PROTEOSYS AG , CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
发明人： CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
IPC分类号： G01N33/68
CPC分类号： G01N33/57415
摘要： The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors.
摘要翻译：本发明涉及一种用人类样品进行蛋白质组学的池化方法，所述人类样品优选地源自显微解剖的人类样品，其中样品被分组为两个或更多个池，并且每个池展示至少一种这些池之间差异明显，但是对于给定池中的成员通用。此外，本发明涉及其丰度在癌细胞中上调的蛋白质，尤其是在乳腺癌细胞中，优选在对激素结合受体为阳性或阴性的乳腺癌细胞中。

58. 发明申请

WO2006008118A1 MUSCARINIC ANTAGONISTS WITH PARP AND SIR MODULATING ACTIVITY AS CYTOPROTECTIVE AGENTS 审中-公开
标题翻译：具有PARP和SIR调节活性作为CYTOPROTECTIVE代理的肌肉拮抗剂
公开(公告)号：WO2006008118A1
公开(公告)日：2006-01-26
申请号：PCT/EP2005/007804
申请日：2005-07-18
申请人： PROTEOSYS AG , SCHRATTENHOLZ, André
发明人： SCHRATTENHOLZ, André
IPC分类号： A61K31/5513
CPC分类号： A61K31/554 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/5517 , A61K31/553
摘要： The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.
摘要翻译：本发明一般涉及混合的毒蕈碱抑制/ PARP调节的细胞保护活性，特别涉及使用M1毒蕈碱受体和聚（ADP-核糖）聚合酶（PARP）的双重抑制剂作为神经保护药物，特别是作为药物预防和/或治疗神经系统疾病。特别优选的化合物是缩合的二氮杂酮，例如缩合苯并二氮杂酮如哌仑西平或代谢为缩合苯并二氮杂酮如奥氮平的化合物。

59. 发明申请

WO2005078124A2 DIAGNOSTISCHE MARKER FÜR KREBS 审中-公开
标题翻译：诊断癌症标记物
公开(公告)号：WO2005078124A2
公开(公告)日：2005-08-25
申请号：PCT/EP2005/001567
申请日：2005-02-16
申请人： PROTEOSYS AG , CAHILL, Michael , KLOCKER, Helmut , ROGATSCH, Hermann
发明人： CAHILL, Michael , KLOCKER, Helmut , ROGATSCH, Hermann
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158
摘要： Es wird die Verwendung verschiedener Proteine als diagnostische Marker für Krebserkrankungen bereitgestellt. Besonders bevorzugt ist die Verwendung des Proteins Annexin A3. Bevorzugterweise wird hierbei eine Heraufregulation von Annexin A3 im Vergleich mit Kontrollen untersucht. Weiterhin wird die Verwendung von Wirkstoffen zur Herstellung eines Medikaments zur Behandlung von Krebs beschrieben, wobei diese Wirkstoffe die Aktivität und/oder die Abundanz verschiedener charakteristischer Proteine beeinflussen.
摘要翻译：提供了使用各种蛋白质作为癌症诊断标志物的。特别优选的是使用所述蛋白膜联蛋白A3的。优选地，在与对照相比膜联蛋白A3的上调在这里调查。此外，使用用于制备用于治疗癌症的药物活性物质的描述，其中这些活性成分影响的活性和/或各种特性的蛋白质的丰度。

60. 发明申请

WO2004099233A3 AFFINITY-BASED ENRICHMENT OF PHOSPHORYLATED PEPTIDES AND/OR PROTEINS 审中-公开
标题翻译：磷酸化的肽和/或蛋白质的亲和富集
公开(公告)号：WO2004099233A3
公开(公告)日：2005-01-27
申请号：PCT/EP2004004405
申请日：2004-04-27
申请人： PROTEOSYS AG , SOSKIC VUKIC , SCHRATTENHOLZ ANDRE
发明人： SOSKIC VUKIC , SCHRATTENHOLZ ANDRE
IPC分类号： B01D15/38 , B01J20/289 , C07K1/22 , B01J20/32
CPC分类号： B01J20/3219 , B01D15/3804 , B01J20/289 , B01J20/3255 , B01J20/3265 , B01J2220/54 , C07K1/22
摘要： The invention relates to a substance comprising a solid carrier that is connected to a spacer by means of a linker, said spacer comprising at least two defined groups. Said substance is suitable for using as an affinity material for enriching and/or isolating phosphorylated peptides and/or proteins. The inventive substance especially enables tyrosine-phosphorylated peptides and/or proteins to be enriched and/or isolated.
摘要翻译：它是提供一种物质，包括通过接头连接到一个隔离件，它带有至少两个特定组固体支持物。这种物质是作为磷酸化的肽和/或蛋白质的富集和/或分离的亲和材料是有用的。特别是，在此酪氨酸磷酸化的肽和/或蛋白质可以富集和/或分离。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式